rs1801155
badMag 6.5This is a protein-altering variant in the APC gene.
Key Literature Trait Associations
Colorectal Cancer Risk
The APC I1307K variant (c.3920T>A, p.Ile1307Lys) creates a hypermutable poly-A repeat (A8 instead of A3TA4) prone to somatic frameshift during DNA replication, meaning it does not directly inactivate APC but renders the gene susceptible to subsequent somatic mutations. Carriers have approximately 1.5–2× the average risk of colorectal cancer. The variant is present in roughly 6–10% of Ashkenazi Jewish individuals and is considerably rarer in other populations. Carriers should discuss colonoscopy surveillance with their physician.
Breast cancer
APC I1307K has been associated with elevated breast cancer risk, primarily in female Ashkenazi Jewish carriers and non-Ashkenazi white women. A large 2016 study of 13,013 healthy subjects and 1,611 cancer patients found an overall adjusted OR of 2.53 (p<0.0001) for any cancer in I1307K carriers, with breast cancer showing increased prevalence among female carriers. A 2022 registry study found OR=1.73 for breast cancer in non-Ashkenazi white female carriers. Evidence is more limited than for colorectal cancer and routine enhanced screening for breast cancer in I1307K carriers is not yet universally recommended.
▶ClinVar annotation
; Breast cancer, susceptibility to; not provided; Familial adenomatous polyposis 1; not specified; Hereditary cancer-predisposing syndrome; Familial multiple polyposis syndrome; Colorectal cancer, susceptibility to; Carcinoma of colon; Colorectal cancer; APC-Associated Polyposis Disorders; Breast carcinoma; Familial colorectal cancer; Diffuse midline glioma, H3 K27-altered
View on ClinVar →▶Research that mentions this SNP (1)
▶Prevalence and Spectrum of Germline Cancer Susceptibility Gene Mutations Among Patients With Early-Onset Colorectal CancerAssociationN=450Pearlman R. et al.(2017)· JAMA Oncology
A prospective cohort study of 450 patients with early-onset colorectal cancer (diagnosed before age 50) identified 72 patients (16%) with pathogenic mutations in cancer susceptibility genes, including 37 with Lynch syndrome (MLH1, MSH2, MSH6, PMS2). The study found that multigene panel testing identified mutations in 33.3% of patients who did not meet conventional genetic testing criteria, suggesting that broad multigene panel testing should be considered for all early-onset CRC patients.
Gene information from NCBI Gene. Variant classifications from ClinVar.
Community Wiki
No community notes yet for this variant. Sign in to start one.
Comments
Sign in to join the discussion.
Loading comments…